Carcinoma, Neuroendocrine

• 

  Subject Areas on Research

  • Altered telomeres in tumors with ATRX and DAXX mutations. 
  • Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. 
  • Evolving application of minimally invasive cancer operations at a tertiary cancer center. 
  • FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. 
  • Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. 
  • MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. 
  • Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. 
  • Neuroendocrine lung tumors and disorders of the neuromuscular junction. 
  • Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. 
  • Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. 
  • Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis. 
  • Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 
  • Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer. 
  • Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation. 
  • Staging of esophageal cancer by EUS: staging accuracy revisited. 
  • Surgical management of medullary thyroid carcinoma. 
  • Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. 
  • The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. 
  • Thyroid carcinoma, version 2.2014. 
  • Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. 
  • Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology